Observational studyTransfusion2026
Prothrombin complex concentrate for oral factor Xa inhibitor reversal prior to urgent invasive procedures.
Observational study in Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral factor Xa (FXa) inhibitors are anticoagulants with no approved reversal agent for use before urgent invasive procedures. Four-factor prothrombin complex concentrate (4F-PCC) is used off-label for this despite limited evidence regarding its effectiveness and safety.
aimsTo determine the efficacy of 4F-PCC prior to urgent invasive procedures in FXa inhibitor-treated patients. Secondary aims were hemoglobin levels and transfusion requirements within 48 h following the procedure, to determine the effect of treatment on anti-FXa levels and to document thromboembolic events and mortality at 30 days.
methodsWe conducted a prospective, single-center observational study of consecutive adults receiving 4F-PCC for reversal of oral FXa inhibitors before urgent invasive procedures with moderate-to-high bleeding risk.
resultsFifty-nine were included in the analysis (median age 78 years). Apixaban was the most frequently used anticoagulant (83.1%). 74.6% underwent urgent surgical procedures and 25.4% underwent other invasive procedures. The median 4F-PCC dose was 2000 units. The primary endpoint of normal or mildly abnormal hemostasis was achieved in 89.8% of patients (84.7% normal, 5.1% mildly abnormal). About 10.2% had moderately abnormal hemostasis; no patients had severe hemostatic failure. Median hemoglobin decline was 1.5 g/dL, with 8.5% of patients requiring red blood cell transfusion. In 17 patients with paired measurements, median decrease in anti-FXa activity was 42%. Thromboembolic events occurred in 5.1%, and 30-day mortality was 10.2%.
conclusionsThromboembolic events were infrequent. These data support the use of 4F-PCC for reversal of FXa inhibitors prior to urgent invasive procedures with a moderate or high bleeding risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.